Non-squamous histology but not adjuvant therapy affects survival in stage IB-IIA cervical cancer patients with intermediate risk following radical hysterectomy

被引:2
作者
Wang, Ying-Wen [1 ]
Lin, Hao [1 ]
Fu, Hung-Chun [1 ]
Chien, Chan-Chao Chang [1 ]
Ou, Yu-Che [2 ]
Lee, Pei-Hang [3 ]
Huang, Chao-Cheng [3 ]
Wu, Chen-Hsuan [1 ,4 ]
机构
[1] Kaohsiung Chang Gung Mem Hosp, Dept Obstet & Gynecol, Kaohsiung 833, Taiwan
[2] Chia Yi Chang Gung Mem Hosp, Dept Obstet & Gynecol, Chiayi 613, Chiayi County, Taiwan
[3] Kaohsiung Chang Gung Mem Hosp, Dept Anat Pathol, Kaohsiung 833, Taiwan
[4] Chang Gung Univ, Grad Inst Clin Med Sci, Taoyuan 333, Taiwan
关键词
Cervical cancer; Intermediate risk; Adjuvant treatment; PELVIC RADIATION-THERAPY; RANDOMIZED-TRIAL; CHEMOTHERAPY; CARCINOMA; CISPLATIN; SURGERY;
D O I
10.31083/j.ejgo4206175
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: Radiotherapy is usually recommended following radical hysterectomy (RH) in early-stage cervical cancer with intermediate risk. However, adjuvant radiotherapy only decreases recurrence but not overall survival. This study aimed to compare different adjuvant modalities's efficacy and to identify prognostic factors among these patients. Methods: A single-center retrospective study was conducted between 2001 and 2015 on FIGO stage IB-IIA cervical cancer patients with intermediate risk following RH. 97 patients were enrolled for analysis. The patients underwent either RH and chemotherapy (n = 24), RH and radiotherapy (n = 21), or RH and close surveillance (n = 52). Prognostic factors that affected disease-free survival (DFS) and overall survival (OS), were compared by Kaplan-Meier analysis. Cox regression was used for univariate and multivariate analyses. Results: The median follow-up period was 117.7 months. There was no statistical difference between 5-year DFS and OS among patients receiving different adjuvant treatments, but patients with non-squamous histology had a lower 5-year DFS (p = 0.014). Multivariate analysis demonstrated no factors but only non-squamous histology significantly predicted DFS (HR = 3.565, 95% CI 1.334-9.531). Conclusions: Non-squamous histology, but not different adjuvant treatment, affects DFS in patients with stage IB-IIA cervical cancer with intermediate pathological risk following RH.
引用
收藏
页码:1205 / 1212
页数:8
相关论文
共 29 条
[11]   Final results of a phase II chemoradiation protocol for locally advanced cervical cancer: RTOG 85-15 [J].
John, M ;
Flam, M ;
Caplan, R ;
Rotman, M ;
Quivey, J ;
Steinfeld, A ;
Russell, A .
GYNECOLOGIC ONCOLOGY, 1996, 61 (02) :221-226
[12]   ETOPOSIDE (VP-16), IFOSFAMIDE MESNA, AND CISPLATIN CHEMOTHERAPY FOR ADVANCED AND RECURRENT CARCINOMA OF THE CERVIX [J].
KREDENTSER, DC .
GYNECOLOGIC ONCOLOGY, 1991, 43 (02) :145-148
[13]   Randomized study between radical surgery and radiotherapy for the treatment of stage IB-IIA cervical cancer: 20-year update [J].
Landoni, Fabio ;
Colombo, Alessandro ;
Milani, Rodolfo ;
Placa, Franco ;
Zanagnolo, Vanna ;
Mangioni, Costantino .
JOURNAL OF GYNECOLOGIC ONCOLOGY, 2017, 28 (03)
[14]   Comparison between adjuvant chemotherapy and adjuvant radiotherapy/chemoradiotherapy after radical surgery in patients with cervical cancer: a meta-analysis [J].
Lee, Kwang-Beom ;
Shim, Seung-Hyuk ;
Lee, Jong-Min .
JOURNAL OF GYNECOLOGIC ONCOLOGY, 2018, 29 (04)
[15]   An analysis of cell type in patients with surgically staged stage IB carcinoma of the cervix: A Gynecologic Oncology Group Study [J].
Look, KY ;
Brunetto, VL ;
ClarkePearson, DL ;
Averette, HE ;
Major, FJ ;
Alvarez, RD ;
Homesley, HD ;
Zaino, RJ .
GYNECOLOGIC ONCOLOGY, 1996, 63 (03) :304-311
[16]   Effectiveness of adjuvant systemic chemotherapy for intermediate-risk stage IB cervical cancer [J].
Matsuo, Koji ;
Shimada, Muneaki ;
Yokota, Harushige ;
Satoh, Toyomi ;
Katabuchi, Hidetaka ;
Kodama, Shoji ;
Sasaki, Hiroshi ;
Matsumura, Noriomi ;
Mikami, Mikio ;
Sugiyama, Toru .
ONCOTARGET, 2017, 8 (63) :106866-106875
[17]   Analysis of the effect of adjuvant radiotherapy on outcomes and complications after radical hysterectomy in FIGO stage IB1 cervical cancer patients with intermediate risk factors (GOTIC Study) [J].
Nakamura, Kazuto ;
Kitahara, Yoshikazu ;
Satoh, Toyomi ;
Takei, Yuji ;
Takano, Masashi ;
Nagao, Shoji ;
Sekiguchi, Isao ;
Suzuki, Mitsuaki .
WORLD JOURNAL OF SURGICAL ONCOLOGY, 2016, 14
[18]  
National Comprehensive Cancer Network, 2019, NCCN GUID CERV CANC
[19]  
National Health Research Institute, 2007, CLIN PRACTICE GUIDEL
[20]   Long-term outcomes of postoperative taxane/platinum chemotherapy for early stage cervical cancer: a retrospective study [J].
Okazawa-Sakai, Mika ;
Yokoyama, Takanori ;
Fujimoto, Etsuko ;
Okame, Shinichi ;
Shiroyama, Yuko ;
Yokoyama, Takashi ;
Takehara, Kazuhiro .
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2018, 23 (04) :715-725